Shots:

• The 4 pivotal HAVEN studies (HAVEN-1- 2- 3- 4) included pooled data from 401 people with hemophilia A with/ out factor VIII inhibitors- with a median duration efficacy period of 120.4wks.
• Hemlibra maintained low treated bleed rates with ABR remaining low throughout the evaluation period at 1.4. The proportion of participants who experienced 0 treated bleeds (70.8-83.7%) increased with each consecutive 24wks. period
• Roche also presented the first interim analysis of the EUHASS database suggesting that the safety profile of Hemlibra in the real-world setting is consistent with the clinical trials- with no new/ emerging safety signals. Hemlibra is a bispecific factor IXa- and factor X-directed Ab

 ­ Ref: GlobeNewswire | Image: Roche